JP2017513900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513900A5 JP2017513900A5 JP2016564149A JP2016564149A JP2017513900A5 JP 2017513900 A5 JP2017513900 A5 JP 2017513900A5 JP 2016564149 A JP2016564149 A JP 2016564149A JP 2016564149 A JP2016564149 A JP 2016564149A JP 2017513900 A5 JP2017513900 A5 JP 2017513900A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence
- sequences
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940125644 antibody drug Drugs 0.000 claims 12
- 239000000611 antibody drug conjugate Substances 0.000 claims 7
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
- 125000006781 (C4-C10) cycloalkylcarbonyl group Chemical group 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305620.8 | 2014-04-25 | ||
| EP14305620 | 2014-04-25 | ||
| PCT/EP2015/059045 WO2015162291A1 (en) | 2014-04-25 | 2015-04-27 | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513900A JP2017513900A (ja) | 2017-06-01 |
| JP2017513900A5 true JP2017513900A5 (enExample) | 2017-08-10 |
| JP6258523B2 JP6258523B2 (ja) | 2018-01-10 |
Family
ID=50630736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564149A Active JP6258523B2 (ja) | 2014-04-25 | 2015-04-27 | Ｉｇｆ−１ｒ抗体−薬物複合体および癌の処置のためのその使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10633448B2 (enExample) |
| EP (2) | EP3498301A1 (enExample) |
| JP (1) | JP6258523B2 (enExample) |
| KR (1) | KR101795984B1 (enExample) |
| CN (1) | CN106456800B (enExample) |
| AU (1) | AU2015250759B2 (enExample) |
| BR (1) | BR112016024619A2 (enExample) |
| CA (1) | CA2946469C (enExample) |
| CY (1) | CY1121783T1 (enExample) |
| DK (1) | DK3134124T3 (enExample) |
| ES (1) | ES2727103T3 (enExample) |
| HR (1) | HRP20190888T8 (enExample) |
| HU (1) | HUE044862T2 (enExample) |
| IL (1) | IL248455B (enExample) |
| LT (1) | LT3134124T (enExample) |
| MA (2) | MA47811A (enExample) |
| MX (1) | MX372912B (enExample) |
| MY (1) | MY186711A (enExample) |
| PL (1) | PL3134124T3 (enExample) |
| PT (1) | PT3134124T (enExample) |
| RS (1) | RS58742B1 (enExample) |
| RU (1) | RU2692563C2 (enExample) |
| SA (1) | SA516380120B1 (enExample) |
| SI (1) | SI3134124T1 (enExample) |
| TN (1) | TN2016000472A1 (enExample) |
| UA (1) | UA120364C2 (enExample) |
| WO (1) | WO2015162291A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA120364C2 (uk) * | 2014-04-25 | 2019-11-25 | Пьєр Фабр Медікамент | Кон'югат антитіла до igf-1r з лікарським засобом |
| RU2728568C2 (ru) * | 2015-10-26 | 2020-07-30 | Пьер Фабр Медикамент | Композиция для лечения рака, экспрессирующего igf-1r |
| EP3427055A1 (en) | 2016-03-07 | 2019-01-16 | Pierre Fabre Medicament | A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples |
| BR112021005655A2 (pt) | 2018-09-27 | 2021-06-29 | Pierre Fabre Medicament | ligantes à base de sulfomaleimida e conjugados correspondentes |
| CN111327570B (zh) | 2018-12-14 | 2021-09-17 | 北京京东尚科信息技术有限公司 | 验证方法、装置和计算机可读存储介质 |
| EP3735991A1 (fr) | 2019-05-06 | 2020-11-11 | Pierre Fabre Medicament | Adc pour un traitement concomitant ou postérieur au docétaxel |
| MY210304A (en) * | 2020-04-02 | 2025-09-10 | Mersana Therapeutics Inc | Antibody drug conjugates comprising sting agonists |
| EP3909612A1 (en) | 2020-05-12 | 2021-11-17 | Life Science Inkubator Betriebs GmbH & Co. KG | Composition of nanoparticles |
| CN118059229A (zh) * | 2020-10-14 | 2024-05-24 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| EP4536280A2 (en) * | 2022-06-10 | 2025-04-16 | Acelyrin, Inc. | Anti-igf-1r antibody compositions |
| EP4353220A1 (en) | 2022-10-12 | 2024-04-17 | Pierre Fabre Medicament | Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate |
| WO2024180233A1 (en) | 2023-03-02 | 2024-09-06 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | A therapeutic hpv vaccine based on validated target epitopes |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2024249596A2 (en) * | 2023-05-31 | 2024-12-05 | Lirum Therapeutics, Inc. | Methods for treating igf-1r-related cancers with an insulin-like growth factor 1 receptor ligand conjugated to a cytotoxic agent |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69434136T2 (de) | 1993-10-01 | 2005-12-01 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin-derivate |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| MXPA06014065A (es) * | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| JP5290756B2 (ja) | 2005-09-26 | 2013-09-18 | メダレックス インコーポレイテッド | 抗体−薬剤コンジュゲート及びその使用 |
| AR064464A1 (es) | 2006-12-22 | 2009-04-01 | Genentech Inc | Anticuerpos anti - receptor del factor de crecimiento insulinico |
| AR065803A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| MY188455A (en) | 2007-10-19 | 2021-12-09 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| DK2276509T3 (en) | 2008-04-11 | 2016-09-19 | Seattle Genetics Inc | DETECTION AND TREATMENT OF CANCER IN PANCREAS, ovarian and other cancers |
| AU2010229192A1 (en) | 2009-03-06 | 2011-09-29 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins |
| WO2010146059A2 (en) * | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| US20110256157A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP5791707B2 (ja) | 2010-06-10 | 2015-10-07 | シアトル ジェネティックス， インコーポレイテッド | 新規アウリスタチン誘導体およびその使用 |
| ES2553874T3 (es) | 2010-09-29 | 2015-12-14 | Seattle Genetics, Inc. | N-Carboxialquil-auristatinas y su uso |
| ES3004351T3 (en) * | 2010-10-22 | 2025-03-12 | Seagen Inc | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| ES2543888T3 (es) | 2011-03-16 | 2015-08-25 | Seattle Genetics, Inc. | N-carboxialquil-auristatinas y su utilización |
| US9150644B2 (en) * | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| US9796754B2 (en) | 2011-05-27 | 2017-10-24 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| ES2898854T3 (es) | 2011-05-27 | 2022-03-09 | Ambrx Inc | Composiciones que contienen, métodos que implican, y usos de derivados de dolastatina enlazados con aminoácidos no naturales |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2858676B1 (en) | 2012-06-07 | 2019-03-13 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
| KR102190832B1 (ko) | 2012-06-19 | 2020-12-15 | 암브룩스, 인코포레이티드 | 항cd70 항체 약물 컨쥬게이트 |
| US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
| EP2885321A4 (en) | 2012-08-14 | 2016-03-30 | Angiochem Inc | CONJUGATES WITH AN ANTIBODY PART, A POLYPEPTIDE THROUGH THE BLOOD BRAIN BARRIER, AND A CYTOTOXIN |
| EP2934596A1 (en) | 2012-12-21 | 2015-10-28 | Glykos Finland Oy | Linker-payload molecule conjugates |
| FR3005051A1 (fr) | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| PL3134125T3 (pl) * | 2014-04-25 | 2020-04-30 | Pierre Fabre Médicament | Koniugat przeciwciało-lek i jego zastosowanie do leczenia raka |
| JP6835591B2 (ja) * | 2014-04-25 | 2021-02-24 | ピエール、ファーブル、メディカマン | Ｉｇｆ−１ｒ抗体および癌処置のためのアドレッシングビヒクルとしてのその使用 |
| UA120364C2 (uk) * | 2014-04-25 | 2019-11-25 | Пьєр Фабр Медікамент | Кон'югат антитіла до igf-1r з лікарським засобом |
| RU2728568C2 (ru) * | 2015-10-26 | 2020-07-30 | Пьер Фабр Медикамент | Композиция для лечения рака, экспрессирующего igf-1r |
-
2015
- 2015-04-27 UA UAA201611833A patent/UA120364C2/uk unknown
- 2015-04-27 MY MYPI2016703874A patent/MY186711A/en unknown
- 2015-04-27 MA MA047811A patent/MA47811A/fr unknown
- 2015-04-27 MA MA39909A patent/MA39909B1/fr unknown
- 2015-04-27 KR KR1020167031683A patent/KR101795984B1/ko active Active
- 2015-04-27 BR BR112016024619A patent/BR112016024619A2/pt not_active Application Discontinuation
- 2015-04-27 MX MX2016013704A patent/MX372912B/es active IP Right Grant
- 2015-04-27 TN TN2016000472A patent/TN2016000472A1/en unknown
- 2015-04-27 EP EP19154902.1A patent/EP3498301A1/en not_active Withdrawn
- 2015-04-27 HU HUE15720045 patent/HUE044862T2/hu unknown
- 2015-04-27 SI SI201530751T patent/SI3134124T1/sl unknown
- 2015-04-27 CN CN201580033382.0A patent/CN106456800B/zh active Active
- 2015-04-27 AU AU2015250759A patent/AU2015250759B2/en not_active Ceased
- 2015-04-27 RU RU2016145444A patent/RU2692563C2/ru active
- 2015-04-27 EP EP15720045.2A patent/EP3134124B1/en active Active
- 2015-04-27 DK DK15720045.2T patent/DK3134124T3/da active
- 2015-04-27 JP JP2016564149A patent/JP6258523B2/ja active Active
- 2015-04-27 PL PL15720045T patent/PL3134124T3/pl unknown
- 2015-04-27 CA CA2946469A patent/CA2946469C/en active Active
- 2015-04-27 PT PT15720045T patent/PT3134124T/pt unknown
- 2015-04-27 ES ES15720045T patent/ES2727103T3/es active Active
- 2015-04-27 US US15/306,351 patent/US10633448B2/en active Active
- 2015-04-27 RS RS20190615A patent/RS58742B1/sr unknown
- 2015-04-27 WO PCT/EP2015/059045 patent/WO2015162291A1/en not_active Ceased
- 2015-04-27 LT LTEP15720045.2T patent/LT3134124T/lt unknown
- 2015-04-27 HR HRP20190888TT patent/HRP20190888T8/hr unknown
-
2016
- 2016-10-23 SA SA516380120A patent/SA516380120B1/ar unknown
- 2016-10-23 IL IL248455A patent/IL248455B/en active IP Right Grant
-
2019
- 2019-05-15 CY CY20191100523T patent/CY1121783T1/el unknown
-
2020
- 2020-02-26 US US16/801,491 patent/US11661457B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513900A5 (enExample) | ||
| RU2016145444A (ru) | Конъюгат антитела против igf-1r с лекарственным средством и его применение для лечения рака | |
| JP2017513904A5 (enExample) | ||
| JP2011046732A5 (enExample) | ||
| JP2020512281A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| JP2018070648A5 (enExample) | ||
| HRP20192254T1 (hr) | Konjugat antitijela i lijeka i njegova upotreba u liječenju karcinoma | |
| JP2019531084A5 (enExample) | ||
| JP2017518040A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| JP2013528569A5 (enExample) | ||
| IL317587A (en) | Antibody against SIRPalpha | |
| JP2020502271A5 (enExample) | ||
| JP2015509947A5 (enExample) | ||
| JP2017519759A5 (enExample) | ||
| JP2018536624A5 (enExample) | ||
| JP2019536740A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| JP2015528818A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2018527884A5 (enExample) | ||
| JP2013505944A5 (enExample) | ||
| JP2014522850A5 (enExample) | ||
| JP2018503380A5 (enExample) |